Newsroom
Sepsis: a new application for the SUL-compounds?
Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD), Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being...
New publications ROKEPIE
Lately there is a lot of happening at Sulfateq which is very positive for the development of ROKEPIE. Besides our new website there are also multiple publications and papers which have been published or will be published in the near future. What’s...
BIO-Europe 2016 – Cologne
From 7 till 9 November 2016 we will be attending BIO-Europe 2016 in Cologne (Germany). BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Our CEO Kees van der Graaf will be present on these days to talk...
The Sulfateq compound SUL-121 is proven to potentially contribute to the treatment of COPD
We are proud to announce that one of our SUL-compounds, SUL-121, is proven to have both an anti-inflammatory and bronchodilating effect in vitro and in vivo. In the study, performed by the University of Groningen, the researchers explored the...
TEDx talk | Prof. Henning about the foundation of our company: Hibernation and Human medicine
On November 20th last year, Prof. Dr. R.H. Henning from the University of Groningen, the Netherlands, gave an interesting TEDx talk about hibernation and its importance for human medicine. TEDx Groningen just recently released the video of this...
Poster presented on FIGON Dutch Medicines Days 2014
Colleague Pieter Vogelaar has presented our poster no. 97 “A new class of compounds for the protection of cells during storage at 2- 8°C” on de FIGON Dutch Medicines Days, held on 6-8 October 2014 in Ede, the Netherlands. Two more posters & one...